The questions and answers provided by Onshow via Anteo highlight...

The questions and answers provided by Onshow via Anteo highlight a couple of risks of not holding ADO – a possible buy-out and a possible exclusivity option.

There will be some watching from the sidelines aware of Anteo, but not yet buying in, cautious particularly with what some may regard as a ‘specie biotech’ and also with the current economic climate, that may be holding them from hitting the buy button. They may be waiting for the first large signing where Anteo will become fully de-risked. A $10-15m royalty signing should be worth around 15-20 cents to ADO and some may say, okay I’ll lose that solid 200-300% gain, but I’ll know that Anteo is now fully viable and profit making and with another 60 companies in the wings I’ll be making alot more over the coming years. This makes reasonable investment sense in a risky environment and something I’d consider doing myself.
However what say that first signing is a very large player, potentially generating $30m in royalty revenue which could be worth around 40c-50c to the Anteo share-price. And indications are that a larger player is now in the final stages of full commercial testing. Again it may be a case of damn, I missed that ‘whale’ but again there’s still another 60 companies out there and Anteo and I can make a lot more from them going forward.
But then what say that first large IVD company goes for a buy-out option of Anteo shares or an exclusivity deal and again indications are that this is a possibility. Either of these options will see a huge appreciation in share-price and is a major risk of not holding at least a small parcel of Anteo.
I won’t put in possible share price values here, but they have the potential to be large and to leave you with a sick feeling if you’re not a shareholder.

At 5.5 cents Anteo makes sound buying against the potential rewards to come over the coming months. With 60+ companies now looking at and testing Anteo’s ‘mix n go’ it is now just coming down to a matter of time. And for a couple of these companies the testing is now coming to a close (with the testing generating results far exceeding expectations).
Remember 60+ companies are looking at Anteo. Anteo hasn’t been a company announcing to the market every month or so another companies interest or a materials transfer agreement like many biotechs trying to inch out another half cent to their shareprice, they have been quietly going about building an impressive portfolio of potential customers in a market worth billions. And these potential clients are some of the largest in the IVD, POS, and medical research arena.
Thats why I'm holding and will continue to hold (and buy when I can).
Seb